New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:09 EDTBIIB, RGLSRegulus Therapeutics and Biogen enter into new collaboration agreement
Regulus Therapeutics (RGLS) announced that it has entered into a new collaboration agreement with Biogen (BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis, or MS, under its Regulus microMarkers division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
News For RGLS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
12:25 EDTRGLSRegulus management to meet with Needham
Subscribe for More Information
07:37 EDTBIIBBiogen removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:19 EDTBIIBBiogen, Sobi report Phase 3 Alprolix paediatric study meets primary endpoint
Subscribe for More Information
07:10 EDTBIIBBiogen Idec, Swedish Orphan Biovitrum AB announce positive Alprolix results
Subscribe for More Information
February 26, 2015
08:15 EDTBIIBBiogen shares likely to continue to advance, says RBC Capital
Subscribe for More Information
February 25, 2015
06:14 EDTBIIBPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 19, 2015
18:25 EDTBIIBPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:08 EDTBIIBBiogen consortium identifies new ALS gene and signaling pathways
Subscribe for More Information
February 18, 2015
16:20 EDTRGLSRegulus reports Q4 EPS (49c), consensus (21c)
Reports Q4 revenue $4.2M, consensus $1.97M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use